Mountain Capital Investment Advisors Inc decreased its holdings in Pfizer Inc. (NYSE:PFE) by 42.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,020 shares of the biopharmaceutical company’s stock after selling 28,433 shares during the quarter. Mountain Capital Investment Advisors Inc’s holdings in Pfizer were worth $1,437,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. raised its stake in Pfizer by 0.8% during the 2nd quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock valued at $13,980,372,000 after buying an additional 3,464,207 shares during the last quarter. State Street Corp boosted its stake in shares of Pfizer by 0.3% in the 1st quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock worth $9,551,162,000 after buying an additional 830,299 shares during the last quarter. Capital World Investors grew its holdings in shares of Pfizer by 19.1% in the first quarter. Capital World Investors now owns 224,808,113 shares of the biopharmaceutical company’s stock worth $7,337,737,000 after acquiring an additional 36,092,723 shares during the period. Bank of New York Mellon Corp increased its position in Pfizer by 1.8% during the second quarter. Bank of New York Mellon Corp now owns 57,111,863 shares of the biopharmaceutical company’s stock valued at $1,867,559,000 after acquiring an additional 1,024,264 shares during the last quarter. Finally, Sanders Capital LLC boosted its position in Pfizer by 5.0% in the second quarter. Sanders Capital LLC now owns 28,282,011 shares of the biopharmaceutical company’s stock worth $1,046,595,000 after purchasing an additional 1,349,012 shares during the last quarter. Institutional investors and hedge funds own 69.08% of the company’s stock.
In related news, Director Ronald E. Blaylock bought 13,000 shares of Pfizer stock in a transaction dated Thursday, August 6th. The shares were acquired at an average cost of $38.55 per share, with a total value of $501,150.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at approximately $154,200. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.08% of the company’s stock.
PFE stock opened at $37.95 on Friday. The stock has a market cap of $210.88 billion, a PE ratio of 15.06, a P/E/G ratio of 2.91 and a beta of 0.67. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $40.97. The company has a 50-day moving average price of $36.59 and a 200 day moving average price of $36.32. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The business had revenue of $11.80 billion during the quarter, compared to the consensus estimate of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.80 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.89 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be paid a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 4.01%. The ex-dividend date is Thursday, November 5th. Pfizer’s dividend payout ratio is presently 51.53%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Understanding Specialty Certificates of Deposit
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.